Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 7c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.41), $0.07 better than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Qualcomm (QCOM) PT Raised to $195 at BofA Securities
• BuzzFeed sells shares to Byron Allen affiliate for $5.8 million